The proto-oncogene Myc drives expression of the NK cell-activating NKp30 ligand B7-H6 in tumor cells

OncoImmunology

Volumn 5, Issue 7, 2016, Pages

  Textor, Sonja ^a   Bossler, Felicitas ^a   Henrich, Kai Oliver ^a   Gartlgruber, Moritz ^a   Pollmann, Julia ^a   Fiegler, Nathalie ^a   Arnold, Annette ^a   Westermann, Frank ^a   Waldburger, Nina ^b   Breuhahn, Kai ^b   Golfier, Sven ^c   Witzens Harig, Mathias ^d   Cerwenka, Adelheid ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c BAYER PHARMA AG   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

B7 H6; Cancer immunotherapy; Myc; NK cells; NKp30

Indexed keywords

MYC PROTEIN; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3;

ARTICLE; CANCER IMMUNOTHERAPY; CHROMATIN IMMUNOPRECIPITATION; DEGRANULATION; DOWN REGULATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LEUKEMIA CELL; LIVER CELL CARCINOMA; LUCIFERASE ASSAY; LYMPHOMA; NATURAL KILLER CELL; NEUROBLASTOMA; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SITE DIRECTED MUTAGENESIS; TUMOR CELL; TUMOR REGRESSION; UPREGULATION; WESTERN BLOTTING;

EID: 84982950065     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1116674     Document Type: Article

References (45)

1. A.Cerwenka, L.L.Lanier. Natural killer cells, viruses and cancer. Nat Rev Immunol 2001; 1:41-9; PMID:11905813; http://dx.doi.org/10.1038/35095564
2. T.Kaifu, B.Escaliere, L.N.Gastinel, E.Vivier, M.Baratin. B7-H6/NKp30 interaction:a mechanism of alerting NK cells against tumors. Cell Mol Life Sci 2011; 68:3531-9; PMID:21877119; http://dx.doi.org/10.1007/s00018-011-0802-7
3. D.H.Raulet, N.Guerra. Oncogenic stress sensed by the immune system:role of natural killer cell receptors. Nat Rev Immunol 2009; 9:568-80; PMID:19629084; http://dx.doi.org/10.1038/nri2604
4. A.Byrd, S.C.Hoffmann, M.Jarahian, F.Momburg, C.Watzl. Expression analysis of the ligands for the Natural Killer cell receptors NKp30 and NKp44. PLoS One 2007; 2:e1339; PMID:18092004; http://dx.doi.org/10.1371/journal.pone.0001339
5. D.Pende, S.Parolini, A.Pessino, S.Sivori, R.Augugliaro, L.Morelli, E.Marcenaro, L.Accame, A.Malaspina, R.Biassoni et al. Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J Exp Med 1999; 190:1505-16; PMID:10562324; http://dx.doi.org/10.1084/jem.190.10.1505
6. G.Ferlazzo, M.L.Tsang, L.Moretta, G.Melioli, R.M.Steinman, C.Münz. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med 2002; 195:343-51; PMID:11828009; http://dx.doi.org/10.1084/jem.20011149
7. M.Vitale, M.Della Chiesa, S.Carlomagno, D.Pende, M.Aric∫, L.Moretta, A.Moretta. NK-dependent DC maturation is mediated by TNFalpha and IFNgamma released upon engagement of the NKp30 triggering receptor. Blood 2005; 106:566-71; PMID:15784725; http://dx.doi.org/10.1182/blood-2004-10-4035
8. N.F.Delahaye, S.Rusakiewicz, I.Martins, C.Ménard, S.Roux, L.Lyonnet, P.Paul, M.Sarabi, N.Chaput, M.Semeraro, V.Minard-Colin et al. Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med 2011; 17:700-7; PMID:21552268; http://dx.doi.org/10.1038/nm.2366
9. M.Semeraro, S.Rusakiewicz, V.Minard-Colin, N.F.Delahaye, D.Enot, F.Vély, A.Marabelle, B.Papoular, C.Piperoglou, M.Ponzoni et al. Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients. Sci Transl Med 2015; 7:283ra55; PMID:25877893; http://dx.doi.org/10.1126/scitranslmed.aaa2327
10. T.I.Arnon, H.Achdout, O.Levi, G.Markel, N.Saleh, G.Katz, R.Gazit, T.Gonen-Gross, J.Hanna, E.Nahari et al. Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus. Nat Immunol 2005; 6:515-23; PMID:15821739; http://dx.doi.org/10.1038/ni1190
11. E.Pogge von Strandmann, V.R.Simhadri, B.von Tresckow, S.Sasse, K.S.Reiners, H.P.Hansen, A.Rothe, B.Böll, V.L.Simhadri, P.Borchmann et al. Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. Immunity 2007; 27:965-74; PMID:18055229; http://dx.doi.org/10.1016/j.immuni.2007.10.010
12. C.S.Brandt, M.Baratin, E.C.Yi, J.Kennedy, Z.Gao, B.Fox, B.Haldeman, C.D.Ostrander, T.Kaifu, C.Chabannon et al. The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J Exp Med 2009; 206:1495-503; PMID:19528259; http://dx.doi.org/10.1084/jem.20090681
13. N.Fiegler, S.Textor, A.Arnold, A.Rölle, I.Oehme, K.Breuhahn, G.Moldenhauer, M.Witzens-Harig, A.Cerwenka. Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells. Blood 2013; 122:684-93; PMID:23801635; http://dx.doi.org/10.1182/blood-2013-02-482513
14. J.Matta, M.Baratin, L.Chiche, J.M.Forel, C.Cognet, G.Thomas, C.Farnarier, C.Piperoglou, L.Papazian, D.Chaussabel et al. Induction of B7-H6, a ligand for the Natural Killer cell activating receptor NKp30, in inflammatory conditions. Blood 122:394-404; PMID:23687088; http://dx.doi.org/10.1182/blood-2013-01-481705
15. E.Schlecker, N.Fiegler, A.Arnold, P.Altevogt, S.Rose-John, G.Moldenhauer, A.Sucker, A.Paschen, E.P.von Strandmann, S.Textor et al. Metalloprotease-mediated tumor cell shedding of B7-H6, the ligand of the natural killer cell-activating receptor NKp30. Cancer Res 2014; 74:3429-40; PMID:24780758; http://dx.doi.org/10.1158/0008-5472.CAN-13-3017
16. S.Adhikary, M.Eilers Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol 2005; 6:635-45; PMID:16064138; http://dx.doi.org/10.1038/nrm1703
17. B.Lüscher MAD1 and its life as a MYC antagonist:An update. Euro J Cell Biol 2012; 91:506-514; PMID:21917351; http://dx.doi.org/10.1016/j.ejcb.2011.07.005
18. A.Albihn, J.I.Johnsen, M.A.Henriksson. MYC in oncogenesis and as a target for cancer therapies. Adv Cancer Res 2010; 107:163-224; PMID:20399964; http://dx.doi.org/10.1016/S0065-230X(10)07006-5
19. R.Dalla-Favera, M.Bregni, J.Erikson, D.Patterson, R.C.Gallo, C.M.Croce. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci U S A 1982; 79:7824-7; PMID:6961453; http://dx.doi.org/10.1073/pnas.79.24.7824
20. R.Taub, I.Kirsch, C.Morton, G.Lenoir, D.Swan, S.Tronick, S.Aaronson, P.Leder. Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc Natl Acad Sci U S A 1982; 79:7837-41; PMID:6818551; http://dx.doi.org/10.1073/pnas.79.24.7837
21. R.C.Seeger, G.M.Brodeur, H.Sather, A.Dalton, S.E.Siegel, K.Y.Wong, D.Hammond. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985; 313:1111-6; PMID:4047115; http://dx.doi.org/10.1056/NEJM198510313131802
22. P.P.Wong, F.Miranda, K.V.Chan, C.Berlato, H.C.Hurst, A.G.Scibetta. Histone demethylase KDM5B collaborates with TFAP2C and Myc to repress the cell cycle inhibitor p21(cip) (CDKN1A). Mol Cell Biol 2012; 32:1633-44; PMID:22371483; http://dx.doi.org/10.1128/MCB.06373-11
23. K.E.Boyd, J.Wells, J.Gutman, S.M.Bartley, P.J.Farnham. c-Myc target gene specificity is determined by a post-DNAbinding mechanism. Proc Natl Acad Sci U S A 1998; 95:13887-92; PMID:9811896; http://dx.doi.org/10.1073/pnas.95.23.13887
24. M.Vita, M.Henriksson The Myc oncoprotein as a therapeutic target for human cancer. Semin Cancer Biol 2006; 16:318-30; PMID:16934487; http://dx.doi.org/10.1016/j.semcancer.2006.07.015
25. S.Textor, N.Fiegler, A.Arnold, A.Porgador, T.G.Hofmann, A.Cerwenka. Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2. Cancer Res 71, 5998-6009; PMID:21764762; http://dx.doi.org/10.1158/0008-5472.CAN-10-3211
26. L.Huergo-Zapico, A.Acebes-Huerta, A.López-Soto, M.Villa-Álvarez, A.P.Gonzalez-Rodriguez, S.Gonzalez. Molecular Bases for the Regulation of NKG2D Ligands in Cancer. Front Immunol 2014; 5:106; PMID:24711808; http://dx.doi.org/10.3389/fimmu.2014.00106
27. A.M.Unni, T.Bondar, R.Medzhitov Intrinsic sensor of oncogenic transformation induces a signal for innate immunosurveillance. Proc Natl Acad Sci U S A 2008; 105, 1686-91; PMID:18223157; http://dx.doi.org/10.1073/pnas.0701675105
28. X.V.Liu, S.S.Ho, J.J.Tan, N.Kamran, S.Gasser Ras activation induces expression of Raet1 family NK receptor ligands. J Immunol 2012; 189:1826-34; PMID:22798674; http://dx.doi.org/10.4049/jimmunol.1200965
29. N.Boissel, D.Rea, V.Tieng, N.Dulphy, M.Brun, J.M.Cayuela, P.Rousselot, R.Tamouza, P.Le Bouteiller, F.X.Mahon et al. BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia. J Immunol 2006; 176:5108-16; PMID:16585609; http://dx.doi.org/10.4049/jimmunol.176.8.5108
30. R.Okita, D.Mougiakakos, T.Ando, Y.Mao, D.Sarhan, E.Wennerberg, B.Seliger, A.Lundqvist, K.Mimura, R.Kiessling. HER2/HER3 signaling regulates NK cell-mediated cytotoxicity via MHC class I chain-related molecule A and B expression in human breast cancer cell lines. J Immunol 2012; 188:2136-45; PMID:22301547; http://dx.doi.org/10.4049/jimmunol.1102237
31. A.Nanbakhsh, C.Pochon, A.Mallavialle, S.Amsellem, J.H.Bourhis, S.Chouaib. c-Myc regulates expression of NKG2D ligands ULBP1/2/3 in AML and modulates their susceptibility to NK-mediated lysis. Blood 2014; 123:3585-95; PMID:24677544; http://dx.doi.org/10.1182/blood-2013-11-536219
32. I.Melero, A.Rouzaut, G.T.Motz, G.Coukos. T-cell and NK-cell infiltration into solid tumors:a key limiting factor for efficacious cancer immunotherapy. Cancer Discov 2014; 4:522-6; PMID:24795012; http://dx.doi.org/10.1158/2159-8290.CD-13-0985
33. G.Sconocchia, S.Eppenberger, G.C.Spagnoli, L.Tornillo, R.Droeser, S.Caratelli, F.Ferrelli, A.Coppola, R.Arriga, D.Lauro et al. NK cells and T cells cooperate during the clinical course of colorectal cancer. Oncoimmunology 2014; 3:e952197; PMID:25610741; http://dx.doi.org/10.4161/21624011.2014.952197
34. D.W.Felsher, J.M.Bishop Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell 1999; 4:199-207; PMID:10488335; http://dx.doi.org/10.1016/S1097-2765(00)80367-6
35. J.Guo, R.A.Parise, E.Joseph, M.J.Egorin, J.S.Lazo, E.V.Prochownik, J.L.Eiseman. Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc-Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice. Cancer Chemother Pharmacol 2009; 63:615-25; PMID:18509642; http://dx.doi.org/10.1007/s00280-008-0774-y
36. J.E.Delmore, G.C.Issa, M.E.Lemieux, P.B.Rahl, J.Shi, H.M.Jacobs, E.Kastritis, T.Gilpatrick, R.M.Paranal, J.Qi et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011; 146:904-17; PMID:21889194; http://dx.doi.org/10.1016/j.cell.2011.08.017
37. J.A.Mertz, A.R.Conery, B.M.Bryant, P.Sandy, S.Balasubramanian, D.A.Mele, L.Bergeron, R.J.Sims3rd. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci U S A 2011; 108:16669-74; PMID:21949397; http://dx.doi.org/10.1073/pnas.1108190108
38. Y.K.Tam, B.Miyagawa, V.C.Ho, H.G.Klingemann Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92. J Hematother 1999; 8:281-90; PMID:10417052; http://dx.doi.org/10.1089/106161299320316
39. D.Dreidax, S.Bannert, K.O.Henrich, C.Schröder, S.Bender, C.C.Oakes, S.Lindner, J.H.Schulte, D.Duffy, T.Schwarzl et al. p19-INK4d inhibits neuroblastoma cell growth, induces differentiation and is hypermethylated and downregulated in MYCN-amplified neuroblastomas. Hum Mol Genet 2014; 23:6826-37; PMID:25104850; http://dx.doi.org/10.1093/hmg/ddu406
40. D.Muth, S.Ghazaryan, I.Eckerle, E.Beckett, C.Pöhler, J.Batzler, C.Beisel, S.Gogolin, M.Fischer, K.O.Henrich et al. Transcriptional repression of SKP2 is impaired in MYCN-amplified neuroblastoma. Cancer Res 2010; 70:3791-802; PMID:20424123; http://dx.doi.org/10.1158/0008-5472.CAN-09-1245
41. W.Wang, B.A.Malcolm Two-stage PCR protocol allowing introduction of multiple mutations, deletions and insertions using QuikChange Site-Directed Mutagenesis. Biotechniques 1999; 26:680-2; PMID:10343905
42. G.M.Hocke, M.Z.Cui, J.A.Ripperger, G.H.Fey. Regulation of the rat alpha 2 macroglobulin gene by interleukin 6 and leukemia inhibitory factor. Folia Histochem Cytobiol 1992; 30:137-9; PMID:1284662
43. M.Peifer, F.Hertwig, F.Roels, D.Dreidax, M.Gartlgruber, R.Menon, A.Krämer, J.L.Roncaioli, F.Sand, J.M.Heuckmann et al. Telomerase activation by genomic rearrangements in high-risk neuroblastoma. Nature 2015; 526:700-4; PMID:26466568; http://dx.doi.org/10.1038/nature14980
44. D.J.Duffy, A.Krstic, T.Schwarzl, D.G.Higgins, W.Kolch GSK3 inhibitors regulate MYCN mRNA levels and reduce neuroblastoma cell viability through multiple mechanisms, including p53 and Wnt signaling. Mol Cancer Ther 2014; 13:454-67; PMID:24282277; http://dx.doi.org/10.1158/1535-7163.MCT-13-0560-T
45. W.Zhang, Y.Yu, F.Hertwig, J.Thierry-Mieg, W.Zhang, D.Thierry-Mieg, J.Wang, C.Furlanello, V.Devanarayan, J.Cheng et al. Comparison of RNA-seq and microarray-based models for clinical endpoint prediction. Genome Biol 2015; 16:133; PMID:26109056; http://dx.doi.org/10.1186/s13059-015-0694-1